论文部分内容阅读
新近召开的国际艾滋病(AIDS)会议上介绍了免疫制品公司生产的由Salk研制的“人类免疫缺陷症病毒(HIV)免疫治疗疫苗”,即去包膜灭活经γ射线辐照的HIV核心疫苗。该疫苗试验对象为103名CD4~+T细胞计数超过550的无症状HIV感染患者。作者采用随机双盲对照试验,在为期1年的试验中对疫苗效果的检查指标有:每4个月用DNA聚合酶链反应(PCR)测新鲜细胞的HIV前病毒负荷(HIV DNA整合入宿主细胞);病毒共培养测病毒量;HIVp24抗体及抗原、淋巴细胞刺激指数;迟发型皮肤超敏反应、体重增加及CD4~+T细胞计数。患者于1、3和6个月时分别接受100μg剂量的疫苗。 结果如下:治疗组与对照组用PCR法检测,其血液中HIV的增殖率(病毒负荷)有明显差异,且后半年差别比前半年更甚。对照组对HIV蛋白的细胞免疫应答下降,而治疗组则显著加强或保持稳定,而且治疗组的抗HIV核心蛋白p24抗体水平也显
The recent International AIDS Conference introduced the immunodeficiency virus (HIV) vaccine produced by Salk, an immunodeficiency virus company, that is, the HIV envelope vaccine that inactivates gamma-irradiated gamma-core vaccines . The vaccine was administered to 103 asymptomatic HIV-infected patients with CD4 + T cell counts in excess of 550. The authors used a randomized, double-blind, controlled trial to test the efficacy of the vaccine in a one-year trial of HIV provirus loading of fresh cells every 4 months (integration of HIV DNA into the host Cells); virus co-culture to measure the amount of virus; HIVp24 antibody and antigen, lymphocyte stimulation index; delayed type of skin hypersensitivity, weight gain and CD4 ~ + T cell count. Patients received 100 μg doses of vaccine at 1, 3, and 6 months respectively. The results are as follows: The treatment group and the control group by PCR method, the blood HIV proliferation rate (viral load) were significantly different, and the second half of the difference even worse than the first half. In the control group, the cellular immune response to HIV protein was decreased, whereas the treatment group was significantly enhanced or remained stable, and the anti-HIV core protein p24 antibody level in the treatment group was also significantly